CRISPR Therapeutics Reports Q2 2026 Financial Results

What Happened
On August 3, 2026, CRISPR Therapeutics AG announced its financial results for the quarter ended June 30, 2026 and other business highlights. The company furnished a press release as Exhibit 99.1 to the Current Report on Form 8-K. The filing states the furnished information (including Exhibit 99.1) is not “filed” for purposes of Section 18 of the Exchange Act. The report was signed by CEO Samarth Kulkarni, Ph.D.

Key Details

• Announcement date: August 3, 2026.
• Reporting period: quarter ended June 30, 2026 (Q2 2026).
• Press release: furnished as Exhibit 99.1 to the Form 8-K (information furnished, not filed).
• Authorized signature: Samarth Kulkarni, Ph.D., Chief Executive Officer.

Why It Matters
This 8-K furnishes CRISPR’s quarterly results and business highlights—key information for investors monitoring earnings, revenue, cash position, and clinical or pipeline updates. Because the detailed numbers and operational highlights are in the furnished press release, investors should review Exhibit 99.1 for the specific financial figures and company commentary. Note the company’s statement that the press release is furnished (not filed), which affects certain legal liabilities under the Exchange Act.